Skip to main content
Equibles
DYN logo

DYN · Dyne Therapeutics, Inc. · Metrics

Track DYN — free

Use DYN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DYN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.03 -0.20 (-1.31%)
Russell 2000 member Rebalance outlook locked
Market Cap
$2.84B
Shares
186.75M
Volume · Oct 19 3.35M Avg daily vol (3M) 2.96M

DYN metrics

63 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.23
Market cap
$2.84B

Price action

20 metrics
Price change (1W)
-4.6%
Price change (30D)
-11.0%
Price change (3M)
-35.1%
Price change (6M)
-23.9%
Price change (YTD)
-22.1%
Price change (1Y)
-7.0%
Trailing year
Price change (5Y)
+5.6%
52-week high
$26.78
52-week low
$14.25
Change from 52-week high
-43.1%
Change from 52-week low
+6.9%
Annualized volatility
77.5%
Annualized volatility (3M)
53.8%
Beta
2.2
RSI (14D)
37.0
Price vs SMA 50
-25.0%
Price vs SMA 200
-21.4%
Avg volume (3M)
2.96M
Relative volume
1.1
Average dollar volume
$60.51M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
186.75M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
4.1
reciprocal yield 24.7%
FCF yield
-16.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2024-09-03

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$536.96M
Net income (TTM)
−$519.41M
Trailing 12 months
Diluted EPS (TTM)
$-3.26
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.56
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-3.54
Operating cash flow per diluted share (TTM)
$-2.65
Free cash flow per diluted share (TTM)
$-2.74
Capital expenditures per diluted share (TTM)
$0.09
R&D per diluted share (TTM)
$2.98
Stock compensation per diluted share (TTM)
$0.33
Book value per share
$5.24

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-74.0%
Return on assets
-52.3%
Debt / equity
0.3
Current ratio
12.0
EBITDA (TTM)
—
Free cash flow (TTM)
−$480.43M
Quick ratio
12.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$476.79M
Latest balance sheet
Cash & equivalents
$676.11M
Total assets
$994.01M
Total debt
$199.33M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$477.82M
Capital expenditures (TTM)
$2.61M
R&D (TTM)
$445.71M
SG&A (TTM)
—
Stock compensation (TTM)
$50.37M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
246
13F filer change QoQ
+17
Institutional ownership
102.2%

Short interest

3 metrics
Short interest
13.9%
Latest settlement · 9.0 days to cover
Days to cover
9.0d
Short-squeeze score
71 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$72.29M
Insider-sentiment score
75 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1818794 CUSIP 26818M108 13F (30d) 16 filings 16 filers Visit website Investor relations